The current clinical overuse of antibiotics is widespread, the mutation and iteration of pathogenic bacteria are accelerating, and the situation of bacterial resistance is becoming increasingly severe. Traditional drug resistance and antimicrobial susceptibility testing suffer from shortcomings such as long turnaround times, complex operational procedures, and large sample consumption, making it difficult to achieve rapid and accurate susceptibility determination, often missing the optimal diagnostic and treatment window. Leveraging the core technologies of microfluidic chips and electrochemical sensing, integrated rapid testing of trace samples can be achieved, enabling efficient drug resistance screening and susceptibility analysis. The detection is sensitive, efficient, and the results are accurate and reliable, providing key technical support for clinical precision medication, standardized anti-infective therapy, and curbing the spread of drug-resistant bacteria.